FDA Pipeline Preview, May 2011 (Eli Lilly, Vertex, Regeneron Pharmaceuticals, Nile Therapeutics, Provectus)

Recent FDA action (through April 2011) related to Liprotamase, Aricept Patch, Telaprevir, Restylane Injectable Gel, VEGF Trap-Eye, Cenderitide, PV-10, INNO-206

Complete response

Recommended for approval

Priority review

Orphan drug designation

© 2023 MJH Life Sciences

All rights reserved.